Skip to main content
MorphoSys AG logo

MorphoSys AG — Investor Relations & Filings

Ticker · MOR ISIN · DE000A3H2XW6 LEI · 529900493806K77LRE72 F Manufacturing
Open in API
Filings indexed 1,418 across all filing types
Latest filing 2019-07-03 Declaration of Voting R…
Country DE Germany
Listing F MOR

About MorphoSys AG

https://www.morphosys.com/

MorphoSys AG is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines, primarily for cancer patients. The company specializes in creating therapeutic monoclonal antibodies, utilizing its long-standing expertise and proprietary technology platforms to generate fully human antibodies. Its research and development efforts are concentrated on building a pipeline of novel treatments to address significant unmet medical needs in oncology. In February 2024, Novartis entered into an agreement to acquire MorphoSys, aiming to integrate its antibody technologies and oncology pipeline.

Recent filings

Filing Released Lang Actions
Declaration of Voting Results & Voting Rights Announcements 2019
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is explicitly titled 'Voting Rights Announcements' and contains detailed tables regarding the 'Notification of Major Holdings' under German Securities Trading Act (WpHG). It reports a change in the percentage of voting rights held by an individual (Mitchell Blutt) in MorphoSys AG, crossing a threshold (from 3.09% to 2.94%). This directly corresponds to the definition of reporting changes in significant share ownership levels, which aligns best with the 'Major Shareholding Notification' category (MRQ). Although the header mentions 'Voting Rights Announcements', the content structure is a formal major holding disclosure, which is a specific type of insider/shareholder activity reporting.
2019-07-03 English
Ad hoc: MorphoSys Increases Financial Guidance for 2019 Following a Milestone Payment for Antibody Otilimab (MOR103/GSK3196165) by GSK
Earnings Release Classification · 99% confidence The document is an 'Ad hoc release according to article 17 MAR' announcing an increase in financial guidance for 2019 due to a milestone payment from GSK. This type of immediate, material information disclosure, often related to corporate events or financial forecasts outside of standard periodic reports (like 10-K or IR), fits best under the general category of regulatory announcements or specific corporate news. Since it is not a full financial report (10-K or IR), a Call Transcript (CT), or a formal Earnings Release (ER) which typically contains detailed period results, and it specifically deals with a change in financial outlook based on a partnership event, it is classified as a general Regulatory Filing (RNS) as it is an ad-hoc disclosure mandated by MAR (Market Abuse Regulation). It is not a specific announcement like DIV, DIRS, or MANG. The document length is substantial (7100 chars), so the RPA rule does not strictly apply, but RNS serves as the best fit for an ad-hoc MAR disclosure. FY 2019
2019-07-03 English
Declaration of Voting Results & Voting Rights Announcements 2019
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is explicitly titled 'Voting Rights Announcements' and contains detailed tables regarding the 'Notification of Major Holdings' under German securities law (WpHG). It details changes in voting rights percentages (e.g., from 3.90% to 3.89%) held by a shareholder (Baillie Gifford & Co) in MorphoSys AG. This directly corresponds to the definition of a Major Shareholding Notification, which tracks changes in significant ownership levels crossing regulatory thresholds. The appropriate code is MRQ.
2019-06-28 English
Declaration of Voting Results & Voting Rights Announcements 2019
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is explicitly titled 'Voting Rights Announcements' and contains detailed tables reporting changes in share ownership ('Notification of Major Holdings') by an individual (Mitchell Blutt) in MorphoSys AG, referencing German Securities Trading Act (WpHG) sections. This directly corresponds to the definition of reporting changes in significant share ownership thresholds. The category 'Major Shareholding Notification' (MRQ) is the most appropriate fit for this type of regulatory filing concerning ownership thresholds crossing.
2019-06-26 English
Correction of a release from 24/06/2019, 20:36 CET/CEST - Ad hoc: MorphoSys Appoints Jean-Paul Kress, M.D., as New Chief Executive Officer
Board/Management Information Classification · 100% confidence The document is explicitly labeled as an "Ad-hoc release according to article 17 MAR" and announces a significant personnel change: the appointment of a new Chief Executive Officer (CEO). This type of immediate, material information disclosure falls under the category of management or board changes. Reviewing the definitions, 'Board/Management Information (Code: MANG)' is the most appropriate fit, as it covers 'Announcement of changes in the company's board of directors or senior management.' Although it is an ad-hoc release, which sometimes defaults to RNS, the specific content points directly to MANG, making it a more precise classification than the general regulatory fallback.
2019-06-24 English
MorphoSys Appoints Jean-Paul Kress, M.D., as New Chief Executive Officer (news with additional features)
Board/Management Information Classification · 100% confidence The document is a press release dated June 24, 2019, announcing the appointment of a new Chief Executive Officer (Jean-Paul Kress, M.D.) and the stepping down of the previous CEO. This content directly relates to changes in senior management personnel. Based on the provided definitions, this aligns perfectly with the 'Board/Management Information' category. Filing Code: MANG. It is not an Earnings Release (ER), Interim Report (IR), or Annual Report (10-K), as it focuses solely on personnel changes.
2019-06-24 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.